This thesis describes the evaluation of novel natural products with antibacterial activity enabled by total chemical synthesis.

Gubbens

Pathogenic bacteria are increasingly resistant to today’s antibiotics. Professor Gilles van Wezel seeks new forms of antibiotics in good bacteria that live in the soil.

Vancomycin is a last-resort antibiotic for the treatment of many Gram-positive bacterial infections, while remaining inactive against Gram-negative strains.

Given the accelerating appearance of antimicrobial resistance, there is an urgent need for more fundamental research into novel antibiotic strategies. The work in this thesis helps to address this global problem by developing new antibiotic compounds, inspired by the antibacterial mechanisms of the…

With the rise of multi-drug resistant bacterial pathogens, the possibility of a post-antibiotic world is quickly becoming reality.

Examining the therapeutic potential of new semisynthetic lipopeptide antibiotics

People who have taken antibiotics in the past three months pay more attention to negative facial expressions, according to research by postdoc Katerina Johnson and assistant professor Laura Steenbergen. This may explain how antibiotics increase the risk of developing depression.

Antibiotics are a class of medicine most people take for granted. But pathogenic bacteria are becoming more and more resistant to our antibiotics, and this poses a great challenge for future treatments. There is thus a great societal need to identify new molecules that can address new targets and be…

The investigations described in this thesis lay out strategies aimed at advancing antibiotic research and development. The examples presented revolve around two main approaches: understanding drug-target interactions and target identification.

Polymyxins are clinically used antibiotics, discovered in mid-20th century. Once abandoned due to excessive nephrotoxicity, they are now used increasingly to address infections caused by multi-drug resistant Gram-negative bacteria.In this thesis, we describe the development and synthesis of analogues…

Can the pink-pigmented microbe Methylobacterium extorquens be genetically engineered to convert the sustainable raw material methanol into antibiotics?

Promotor: Prof.dr. G.P. van Wezel

Utilization of plant-originated products as new antibiotics

Can cyclic peptides provide a new generation of antibiotics?

Antimicrobial resistance (AMR) is the phenomenon that pathogens become insensitive to the antibiotics that we use against them. A growing number of pathogens is becoming resistant, with methicillin-resistant S. aureus (MRSA) as the most famous example. But while the threat of AMR represents a slow-moving…

Can effective synergists be identified to enhance the effect of antibiotics against Gram negative pathogens?

Bacteria are highly complex and diverse organisms that have adapted to survive in ecological niches ranging from the most extreme to the most heterogeneous environments.

Global healthcare is on the verge of an antibiotic availability crisis as bacteria have evolved resistance to nearly all known antibacterials. Identifying new antibiotics that operate via novel modes-of-action is therefore of high priority.

Can new variants of daptomycin and the polymyxins be found?

How can cell wall engineering approaches be used to improve streptomycetes for industry to make new antibiotics?

This thesis describes the structural and biochemical characterization of the β-lactamase BlaC from Mycobacterium tuberculosis (Mtb), and the Alr and YlmE proteins from Streptomyces coelicolor A3(2).Mtb is the main cause of tuberculosis.

The prevalence of obesity (BMI >40 kg/m2) has increased rapidly over the recent years, not only in adults, but also in children and adolescents.

Promotor: G.P. van Wezel, Co-promotor: Y.H. Choi

Streptomyces are filamentous bacteria that produce more than two-thirds of known antibiotics.

Through his project we will unravel the global regulatory networks that control gene expression in Streptomyces bacteria and allow them to properly respond to major changes in the environment; we will then harness this knowledge to activate and identify novel antibiotics

Actinobacteria are Gram-positive bacteria that have a complex multicellular life cycle and are well known for their ability to produce a wide range of bioactive natural products (NPs).

Aim of the proposal is to develop lugdunomycin into a drug candidate able to treat infectious diseases caused by multi-drug resistant pathogens.

Extending our current arsenal of antibiotics is key to staying ahead in the arms race between humans and resistant bacteria.

Timely, adequate and optimal treatment of infectious diseases is essential for the survival of patients with bacterial infections (Surviving Sepsis campaign).

'What nature made isn’t necessarily an optimized medicine to use in the human body,’ says Professor of Biological Chemistry Nathaniel Martin. That’s why a group of Leiden researchers is making a chemistry-based improved version of the frequently used antibiotic vancomycin. They received an NWO NACTAR…

Streptomyces are multicellular, Gram-positive bacteria in the phylum of actinobacteria which produce a high amount of bioactive natural products of which the expression is tightly coordinated with the life cycle.

Ontwikkeling van resistentie tegen antibiotica kan optreden als patiënten onnodig of te lang met antibiotica behandeld worden. Diagnostiek waarmee snel een bacteriële infectie vastgesteld kan worden, of de response op antibiotica bepaald kan worden, zijn daarom belangrijk om therapie te optimaliseren…

Streptomycetes are similar to moulds, but these bacteria live in the soil. They are very popular in biotechnology because they produce a great many antibiotics and enzymes. Gilles van Wezel will be using his Vici subsidy to study ways of increasing their production.

Can we make a better vancomycin?

Increasing resistance and a lack of new antibiotics are a serious problem for public health. Against this background, Gilles van Wezel of the Institute of Biology Leiden is looking for new medicines. Together with former PhD student Changsheng Wu and colleagues he discovered the special antibiotic lugdunomycin,…

Antibiotic resistance is a common problem among patients. The European Project TIPAT trains pharmacologists, microbiologists and immunologists of six universities in interdisciplinary thinking. The ultimate goal is to develop better treatment guidelines to combat resistance. Coen van Hasselt of the…

When a bacterium becomes more resistant to one antibiotic, it sometimes becomes more sensitive to another. To better understand this interaction, researchers from the Leiden Institute of Biology (IBL) and the Leiden Academic Center for Drug Research (LACDR) under supervision of Daniel Rozen and Coen…

Resistance to antibiotics is a major problem in health care. Thanks to a grant from the Elise Mathilde Fund and the LUF, pharmacologist dr. Coen van Hasselt can look for new dosing schedules to reduce the development of antibiotic resistance.

When you become very good at one thing, that sometimes comes at the expense of something else. Such trade-offs also apply to bacteria. When becoming more resistant to one antibiotic, bacteria can sometimes become more sensitive to another. Linda Aulin, PhD candidate in the pharmacology group of Coen…

Current means of fighting bacteria are no longer as good as they used to be because of antibiotic resistance. These days, people are dying from bacterial infections that could have been cured fifty years ago.

Bacteriophages, viruses that infect bacteria, may be used as an alternative treatment option when antibiotics fail. Leiden researchers have studied the structure and function of a novel bacteriophage that could be used to treat one of the WHO bacterial strains of concern where new treatments are urgently…

No, this isn’t about a Star Wars Alliance that wants to suppress The Resistance. Rather, the EPIC Alliance brings together scientific experts from seven countries to address the growing threat of antibiotic resistance. Leiden professor Nathaniel Martin is part of the 11-member consortium.

Antibiotic resistance is an economic problem. Pharmaceutical companies cannot earn much from antibiotic research, so they do not invest in it. This makes it important that universities do so, says Ned Buijs.

Prof. Gilles van Wezel and Prof. Mike Richardson of the Institute of Biology Leiden received €1.4 million to find new antibiotics.

Soil bacteria can produce a wealth of antibiotics that are new to us, claims Gilles van Wezel, Professor of Molecular Biotechnology at the Institute of Biology Leiden. His research group has developed a method that can rapidly identify and produce these unknown compounds.

Biological chemist Nathaniel Martin is going to test an alternative antibiotic that can combat common resistant bacteria such as MRSA. For this purpose, he will receive 350,000 euros from the NWO's NACTAR programme. ‘We want to know how safe and effective our antibiotic is in a realistic situation.’

An international consortium of research groups is aiming to develop novel antibiotics against the tuberculosis bacteria and two other deadly bacteria. The European Union has awarded a total of 18 million euros to the RespiriTB and RespiriNTM projects. Researchers from the Leiden University Medical Centre…

To facilitate the search for new antibiotics. That is the aim of Gilles van Wezel, professor molecular biotechnology at the Institute of Biology Leiden (IBL). He wants to do this by looking at similarities in the DNA of antibiotic-producing bacteria. Van Wezel has been awarded an ERC Advanced grant…

Antibiotic resistance, caused by widespread use of antibiotics, leads to bacterial infections that are difficult, if not impossible, to treat and is a major worldwide health concern.